Gene · 24137
KIF4A: kinesin family member 4A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KIF4A: kinesin family member 4A. Genes, record 24137. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/24137
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O95239 | Chromosome-associated kinesin KIF4A | 1,232 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents16
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 50884 | O95239 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9713 | O95239 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5619 | O95239 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9713 | O95239 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5619 | O95239 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 44330 | O95239 | Espacenet |
| JP 2022092366 A | 2022-06-22 | 802 | O95239 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 147301 | O95239 | Espacenet |
| KR 1020210129616 A | 2021-10-28 | 8 | O95239 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 5893 | O95239 | Espacenet |
1 to 10 of 16
See all 16 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants538
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KIF4A papers | Newest fiscal year |
|---|---|---|---|
| R35GM119455 | Mechanisms of Phosphorylation Signaling by Phosphoprotein Phosphatases | 5 | 2025 |
| P20GM113132 | The Institute for Biomolecular Targeting | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 3 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 3 | 2025 |
| P30CA023108 | Cancer Center Support Grant | 3 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 3 | 2025 |
| P20GM103449 | Vermont Biomedical Research Network-Vermont INBRE | 2 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 538Source NIH's project files
See all 538 nih grantsPapers1,342
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| KIF4A stabilizes TDP43 to promote DNA damage repair and temozolomide resistance in glioblastoma. | Biochem Pharmacol | 2026 | 42785594 | PubTator, text mining | PubMed |
| KIF4A drives esophageal squamous cell carcinoma via Wnt/β‑catenin signaling and predicts poor prognosis. | Mol Med Rep | 2026 | 42725385 | PubTator, text mining | PubMed |
| Kinesins in Bladder Cancer: Integrating Molecular Mechanisms and Treatment Approaches. | Cell Biol Int | 2026 | 42529891 | PubTator, text mining | PubMed |
| KIF4A-KIF4B Paralog as a Prognostic Biomarker in Lung Adenocarcinoma. | Medicina (Kaunas) | 2026 | 42512966 | PubTator, text mining | PubMed |
| A bioinformatics analysis of KIF transcriptomic subtyping reveals prognostic heterogeneity and differential therapeutic responses in cervical cancer. | Oncol Lett | 2026 | 42491333 | PubTator, text mining | PubMed |
Retraction notice to "Integrative PPI network and random forest analysis identifies KIF4A, TOP2A, and ASPM protein macromolecules as novel protein biomarkers in renal carcinoma pathogenesis" [International Journal of Biological Macromolecules 311 (2025) 144058]. | Int J Biol Macromol | 2026 | 42486758 | PubTator, text mining | PubMed |
| ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target. | Front Oncol | 2026 | 42459306 | PubTator, text mining | PubMed |
| Reanalysis of Public Transcriptomes Reveals Shared Immune Signatures Between Major Depressive Disorder And Dermatomyositis With Single-Cell Context. | J Vis Exp | 2026 | 42441576 | PubTator, text mining | PubMed |
| Acidosis-associated gene signature defines novel subtypes and dual-target therapeutic candidates in breast cancer. | J Transl Med | 2026 | 42374456 | PubTator, text mining | PubMed |
| Low KIF4A expression is associated with gastric cancer progression and aggressive phenotypes. | Sci Rep | 2026 | 42251143 | PubTator, text mining | PubMed |
1 to 10 of 1,342
See all 1,342 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/24137
GET https://conductscience.org/api/genes/v1/24137/patents